WEBINAR INFORMATION

“Discover a New Investigational Approach to VWD Treatment”

Star Therapeutics’ is investigating a once-monthly subcutaneous prophylactic treatment for VWD called VGA039.

If you or someone in your family has any type of VWD, please join us for an engaging session as Dr. Laura Guido, Head of Medical Affairs at Star Therapeutics, shares how VGA039 works, its clinical development path, and early trial results. Dr. Guido will also discuss our VIVID Clinical Trials and how to explore eligibility and participate. Bring your competitive spirit as you learn more through our interactive trivia!

ABOUT THE SPEAKER:  Laura Guido PharmD, MBA, BCPS, Executive Director, Medical Affairs at Star Therapeutics. Dr. Guido is a clinical pharmacist and leads Medical Affairs for VGA039 at Star Therapeutics. Previously, she supported clinical development for hemophilia A gene therapy trials at BioMarin and spent numerous years in anticoagulation at Boehringer Ingelheim. Prior to joining industry, Dr. Guido was a clinical pharmacist.

THANK YOU TO STAR THERAPEUTICS FOR YOUR SPONSORSHIP!

Note: Session will be presented in English. Zoom link will be sent out prior to the meeting.